


Inmune Bio, Inc. (INMB)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001711754

Inmune Bio, Inc.		
INMB; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it  Rescans on file: D/E from Apr 21, 2025
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$32.4M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	thin data, degenerate inputs; fortress balance sheet not computable: short runway, distress	
Inputs computable	6 of 14	
Graded from	filings received through Mar 30, 2026 193 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026	
Last close	\$1.84 2026-10-08; market equity \$51.2M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction Program: CORDStrom? for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform. RDEB is a devastating pediatric orphan disease caused by mutations in the COL7A1 gene.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 6.7						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(64.9%)	(6.6%)	6.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 63.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(23.76)	(0.31)	76.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Current ratio		3.55x	2.96x	51.3	839	2025-12-31
Growth and financing, sleeve percentile 81.1						
Revenue growth, three-year compound		(48.9%)	10.0%	95.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 1
Reinvestment rate		not computable	37.1%			required facts have no common fiscal period end
Asset growth, three years		(26.6%)	2.1%	90.6	704	2025-12-31
Net share issuance, one year		15.9%	2.5%	57.0	634	2026-03-30

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 5,922,000 USD; Altman Z is not used

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	11.1%	8.0%	52
Distance from 52-week high	(27.1%)	(31.4%)	56

EBIT to enterprise value	(115.5%)	(1.5%)	5
Free cash flow yield	(46.5%)	(1.0%)	13
Book value to price	0.40	0.28	62
Sales to price	0.00	0.31	3
Composite equity issuance, five years	62.0%	20.3%	69
Relative strength against the sector, log excess return	(0.11)	(0.14)	52

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$693,885

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$45.9M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$22.6M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
3	assets	us-gaap:Assets	\$32.4M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
4	assets	us-gaap:Assets	\$39.6M	2024-12-31	2026-03-30	10-K	0001213900-26-036370
5	current assets	us-gaap:AssetsCurrent	\$29.9M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
6	current liabilities	us-gaap:LiabilitiesCurrent	\$8.4M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$209.0M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
8	operating income	us-gaap:OperatingIncomeLoss	-\$47.4M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
9	book equity	us-gaap:StockholdersEquity	\$23.5M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
10	liabilities	us-gaap:Liabilities	\$8.8M	2025-12-31	2026-03-30	10-K	0001213900-26-036370
11	operating income	us-gaap:OperatingIncomeLoss	-\$42.6M	2024-12-31	2026-03-30	10-K	0001213900-26-036370
12	interest expense	us-gaap:InterestExpense	\$789,000	2024-12-31	2025-03-27	10-K	0001013762-25-003354
13	revenue	us-gaap:Revenues	\$50,000	2025-12-31	2026-03-30	10-K	0001213900-26-036370
14	revenue	us-gaap:Revenues	\$14,000	2024-12-31	2026-03-30	10-K	0001213900-26-036370
15	revenue	us-gaap:Revenues	\$155,000	2023-12-31	2025-03-27	10-K	0001013762-25-003354
16	revenue	us-gaap:Revenues	\$374,000	2022-12-31	2024-03-28	10-K	0001213900-24-027206
17	assets	us-gaap:Assets	\$57.0M	2023-12-31	2025-03-27	10-K	0001013762-25-003354
18	assets	us-gaap:Assets	\$81.8M	2022-12-31	2024-03-28	10-K	0001213900-24-027206
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	26,585,258	2026-03-30	2026-03-30	10-K	0001213900-26-036370
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,930,311	2025-03-27	2025-03-27	10-K	0001013762-25-003354